This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales
by Zacks Equity Research
ALKS beats second-quarter estimates as proprietary product sales rise 14% y/y, offsetting weaker manufacturing and royalty revenues.
Alkermes (ALKS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of +26.83% and +15.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
by Zacks Equity Research
EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
by Zacks Equity Research
Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
by Zacks Equity Research
Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.
How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19%
by Zacks Equity Research
The consensus price target hints at a 33.2% upside potential for Alkermes (ALKS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill
by Zacks Equity Research
MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
by Zacks Equity Research
Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
by Zacks Equity Research
Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.
Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore
by Zacks Equity Research
EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty.
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.
ALKS or CSLLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALKS vs. CSLLY: Which Stock Is the Better Value Option?
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates
by Zacks Equity Research
ALKS' earnings and revenues lag first-quarter 2025 estimates. Sales of proprietary products surpass management's expectations.
Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of -53.57% and 3.22%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Alkermes Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Alkermes stock based on the movements in the options market lately.
Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.